Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Reimbursement News › Novitas Announces Future Non-Coverage of Opko's 4Kscore Prostate Cancer Test

Novitas Announces Future Non-Coverage of Opko's 4Kscore Prostate Cancer Test

Feb 01, 2019
|
staff reporter

NEW YORK (360Dx) – Opko Health announced that Medicare administrator Novitas Solutions has issued a notice of future non-coverage determination for the company's 4Kscore prostate cancer test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.